LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Kodu・Aktsiate loetelu・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Suletud

1.68 1.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.5899999999999999

Max

1.69

Põhinäitajad
By Trading Economics
Sissetulek	-23T -3.5M
Aktsiakasum	-0.06
Töötajad	7
EBITDA	-3.5T -3.5T

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+223.53% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	8.4M 106M
Eelmine avamishind	0.48
Eelmine sulgemishind	1.68

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.9 / 2.65 Toetus ja vastupanu

Aldeyra Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. märts 2026, 13:34 UTC

Suurimad hinnamuutused turgudel

Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns

16. dets 2025, 11:43 UTC

Suurimad hinnamuutused turgudel

Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

Võrdlus sarnastega

Hinnamuutus

Aldeyra Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

223.53% tõus

12 kuu keskmine prognoos

Keskmine 5.5 USD 223.53%

Kõrge 9 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Aldeyra Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Aldeyra Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.9 / 2.65Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.